Method for prediction of endometrial hyperplasia in patients with hysteromyoma following uterine artery embolisation

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and concerns a method for the prediction of endometrial hyperplasia in the patients with hysteromyoma following uterine artery embolisation (UAE). Substance of the method: all the patients undergo a pre-UEA diagnostic and therapeutic uterine scrapping; 6 months after the UAE, an endometrial pipelle biopsy followed by a pathomorphological study of the biopsy material is conducted. If the study shows no pathology, the biopsy materials are analysed by means of an immune histochemical study using anti-Ki-67 monoclononal antibodies; a percentage of Ki-67 proliferation marker in the uterine gland epithelium (coefficient A) and in the endometrial stroma (coefficient B) is determined; a prognostic index D1 is calculated in initial(pre-UEA) non-atypical hyperplasia, and a prognostic index D2 - in initial (pre-UEA) endometrium in the late proliferation phase: D1=A*0.05-0.74 and D2=B*0.02-0.3. If D1 is 0 or more, recurrent endometrial hyperplasia is predicted, whereas D1 less than 0 enables stating a low risk of recurrent endometrial hyperplasia. If D2 is more than 0, a low risk of developing endometrial hyperplasia is stated, whereas D2 of 0 or less shows developing endometrial hyperplasia.

EFFECT: presented method enables the high-accuracy prediction of the post-UEA endometrial hyperplasia that makes it possible to prescribe the preventive hormone therapy in due time.

4 ex

 

Scope: the present invention relates to the field of medicine, namely to gynecology.

The level of technology

Uterine artery embolization (UAE) is a modern highly effective method of organ preservation treatment in patients with uterine leiomyoma, which occupies one of leading places in the structure of gynecological morbidity and tending to a steady growth [Sidorova I. S. 2013, vikhlyaeva E. M. 2006]. The effectiveness of EMA according to various sources ranges from 70 to 96% [S. A. Kapranov et 2007, Ishchenko A. I. 2004, L. A. Tikhomirov 2002]. In patients with uterine cancer is often detected endometrial pathology, with clinical symptoms of fibroids are largely determined by the form of hyperplasia, which represents a risk factor of recurrence and formation of atypical forms [SV Sakalakala, 2005].

Researchers [Kogan E. A. 2013, Litvinova N. And. 2011] noted that the immunohistochemical study of different variants of endometrial pathology in patients with uterine myoma a disbalance between steroid hormone receptors, as well as possible correlation between the proliferative processes in the endo - and myometrium, proving a close relationship between the development of these pathological processes. However, the authors have not formulated a specific way immunohistochemical parameters for prediction./p>

Counterparts. Known method for the diagnosis of endometrial hyperplastic processes in patients with uterine fibroids, which consists in determining the indicators of catalase, catalase numbers, malonic dialdehyde in the supernatant of the washings from the uterus or menstrual blood simultaneously (RU # 2007101040, publ. 09.01.2007). However, the definition data of the enzymatic parameters requires special laboratory equipment.

Known method for the diagnosis of endometrial hyperplastic processes, including quantitative determination of the content of biologically active substances in the blood. Determine the number of lysosomal enzyme b-D-glucuronidase and at a level of from 0.01 to 0.02 nmol/min/mg diagnose endometrial hyperplasia (RU # 2159441, publ. 20.11.2000).

The known method of early diagnosis of benign endometrial hyperplastic processes, including venous blood sampling, analysis on the content of products of lipid peroxidation - malondialdehyde. Additionally, the red blood cells determine the primary products of peroxidation of lipids: digestion and diene conjugates, the activity of antioxidant enzymes: glutathione peroxidase and catalase expect the ratio of these indicators, on the basis of which diagnose endometrial hyperplasia (RU # 2190221, publ. 27.09.2002).

Insufficient�mended the known methods, they face the challenge of diagnosis of endometrial hyperplastic processes, and not predicting the risk of development.

Prototype

There is a method of predicting risk of development of endometrial hyperplasia in women with genital endometriosis (EN No. 2468367), namely that the patient is isolated DNA from peripheral venous blood, receive data about the genetic polymorphism-308G/A of tumor necrosis factor α. In case of detection of -308 a allele And patients with genital endometriosis have a higher risk of developing endometrial hyperplasia. The use of the method allows to predict the risk of endometrial hyperplasia among patients with genital endometriosis and based on this determine further tactics of managing such patients. This method cannot be used for patients with uterine cancer (which is one of the most common benign tumors), who takes the EMA as a method of treatment.

Summary of the invention

The aim of the invention is to provide a method of predicting the development of endometrial hyperplasia after treatment with uterine artery embolization.

The method is as follows:

Patients with indications for EMA due to the presence of uterine fibroids, hysteroscopy used, diagnostic curettage at 12-14 days menstr�sexual cycle. Spend pathomorphological examination of scrapings according to standard methods. The resulting material was fixed in 10% neutral formalin and prepared slices with a thickness of 5-6 µm and stained with hematoxylin eosin.

Depending on the histological outcome of patients divided into two groups

Group I - simple or complex endometrial hyperplasia without atypia.

Group II - the endometrium of the late phase of cell proliferation.

All patients carried out EMA on conventional technology with advanced puncture of the femoral artery by Seldinger's method [4] and the review by angiography using polyvinyl alcohol particles (PVA) of the company "the Cook". The introduction of embolisate is stopped when the stop of blood flow in uterine arteries.

6 months after embolization conduct PayPal-endometrial biopsy in subsequent pathologic examination of the biopsy.

The biopsy specimens of patients without any pathology of the endometrium on histology, is additionally subjected to immunohistochemical study on conventional technology [4]. As the primary specific antibodies using monoclonal antibodies to Ki-67 (Cell Marque clone SPI, 1:100). Used streptavidin detection system KP-500. For unmasking antigens apply the procedure of boiling dewaxed sections in a water bath for 1 hour when used�the use of citrate buffer (pH 6.0). Evaluation was carried out by counting the number of stained nuclei in epithelial cells of glands in percent (%) by number of stained cells.

Immunohistochemical study allows to determine the percentage of the proliferation marker Ki-67 in the epithelium of endometrial glands (factor A) and in the stroma of the endometrium (coefficient B).

The values obtained are used to calculate the prognostic index (D1and D2according to the formula developed by using the method of discriminant analysis.

Group I: (D1=A×0,05-0,74;

Where A is the percentage of the proliferation marker Ki-67 in the epithelium of endometrial glands.

At D1that is more than 0 or equal to 0, predict imminent relapse of endometrial hyperplasia.

At D1less than 0 make a conclusion of low risk of recurrence of endometrial hyperplasia.

The sensitivity of the detection algorithm to the elements of group 1 is 92,86%, the efficiency of 94,46%

Group II: D2=In×0,02-0,30;

where b is a percentage of the proliferation marker Ki-67 in endometrial stroma.

At D2over 0 judged low risk of development of endometrial hyperplasia.

At D2, less than 0 or equal to 0, predict the inevitable development of endometrial hyperplasia.

The sensitivity of the detection algorithm to the elements of group 2 is 83,33%,the efficiency 99,00%

Example 1. Patients�ntca In -, 37 years, with complaints of analiziruya menstruation for 12 months. Received for hosting the EMA in connection with the presence of multiple, including submucous localization, uterine fibroids large size (the maximum node up to 90 mm in diameter). In the anamnesis the patient conservative myomectomy, recurrent rapid growth nodes. Pathomorphological examination after treatment and diagnostic curettage revealed the presence of simple glandular endometrial hyperplasia without atypia (group 1). Held EMA has led to good clinical results: normalized menstrual function, according to clinical tests Hb was 128 g/l, ultrasound (US) and Doppler study showed a decrease in the total volume of the uterus is more than 2.5 times, no power at all nodes. PayPal biopsy and histological study at 6 months confirmed late proliferation phase, however, the immunohistochemical studies were obtained the following parameters Ki-67: in the stroma of 20%, in the epithelium of the glands 25%

Under the proposed rule, the calculated coefficient D1for 1 group:

D1=And×0,05-0,74=25×0,05-0,74=0,51>0.

Therefore, the risk of formation of hyperplastic process is inevitable.

The patient offered hormonal therapy (didrogesteron), about the refusal which it announced in 3 months, motiver�I associated with the treatment of headaches. On ultrasound 9 months after EMA was determined by increased M-echo, simple glandular hyperplasia according to histological analysis. The patient underwent microwave endometrial ablation.

Example 2.

Patient D to L. V., 52 years old, was admitted for hysteroscopy and diagnostic curettage with subsequent embolization about uterine fibroids and diagnosed by ultrasound endometrial hyperplasia with complaints of profuse, painful menstruation for 6 years. From the proposed surgical treatment of a patient refused for religious reasons. Histological examination of scrapings confirmed the presence of complex endometrial hyperplasia without atypia. Procedure EMA and postembolization period passed without features. Within 6 months was observed persistent regression of all components and the clinical manifestations of fibroids. 6 months after embolization held PayPal-endometrial biopsy was verified by the endometrium without pathology. Immunohistochemical study revealed the percentage distribution of the proliferation marker Ki-67 in the stroma 32%, in the epithelium of 12%.

Under the proposed rule, the calculated coefficient D1for 1 group:

D1=And×0,05-0,74=12×0,05-0,74=-0,14<0.

On the basis of the result concluded that the risk of recurrence of hyperplasia minimal. The patient was under the supervision of our clinic 12 months�CET during which clinical and ultrasound signs of endometrial pathology was not determined.

Example 3.

The patient To the Islands, 45 years old, was admitted to the gynecology Department for hysteroscopy and diagnostic curettage, presenting complaints of irregular heavy period for 1 year. By ultrasound were determined multiple, including submucosal fibroids (nodes 24 to 48 mm). History: was observed with a diagnosis of uterine fibroids 3 years, seen a gradual growth. Histological examination of scrapings of the endometrium indicated the absence of endometrial pathology. From surgical treatment, the patient adamantly refused. EMA conducted successfully. Postembolization period without complications. On ultrasound there was a decrease in the size of the nodes, and the increase in the extent of their prolabirovanie into the cavity. Histological examination of PayPal-biopsy at 6 months showed no endometrial pathology. However, immunohistochemical parameters were: Ki-67 in the stroma of 15%, in the epithelium of 20%.

Under the proposed rule, the calculated coefficient D2for 2 groups:

D2=×0,02-0,30=15×0,05-0,30=0.

Given the value of D2predict a high risk of developing endometrial hyperplasia. On the basis of these data and the fact that in the uterus by ultrasound after 3 month� was a node of type 2, the patient underwent heteroresistance. Morphological examination confirmed the presence of a simple glandular hyperplasia without atypia, fragments submucous node. At follow-up within 6 months was observed persistent regression of the nodes, the linear cavity of the uterus, the endometrium, the corresponding phase of the cycle.

Example 4.

Patient H -, aged 38, was admitted for hysteroscopy and diagnostic curettage and subsequent EMA in connection with the rapid growth of uterine fibroids by ultrasound. Subjectively, the patient didn't bother. Histological examination of scrapings before EMA did not reveal pathological changes in the endometrium. EMA was performed without complications. Postembolization period without features. The size of the site for 6 months decreased by 65%, while the control of Doppler imaging - a node that has no power. After 6 months were followed up PayPal-endometrial biopsy. Subsequent morphological study was verified by proliferative-phase endometrium. Immunohistochemical indices of Ki-67 in the stroma 30, in epithelium - 26%.

Under the proposed rule, the calculated coefficient D2for 2 groups:

D2=×0,02-0,30=30×0,02-0,30>0.

According to the value of D2>0 the risk of hyperplasia minimal. The patient continued surveillance for 1.5 years, an additional purpose�eny was not required.

Thus, the proposed method allows high accuracy to predict the development of endometrial hyperplasia after embolization, which gives the opportunity to assign preventive hormone therapy.

Sources of information

1. Sidorova I. S., Ageev M. B. Clinico-morphological features simple and proliferating uterine fibroids, Ross. Bulletin of obstetrician-gynecologist, 2013, №6, 34-38.

2. Vikhlyaeva E. M. Manual of endocrine gynecology. M: MIA 2006; 463-551.

3. Kapranov S. A., Grishin I. I., Ozerov R. I., Alieva A. A., Ibragimova M. D., Litvinova N. And. Concomitant pelvic surgery for uterine artery embolization in patients with uterine myoma // Journal of obstetrics and female diseases, special issue, materials of the 3rd International Scientific Congress "New technologies in obstetrics and gynecology", 2007 - volume LVII - c.217-218

4. Ishchenko A. I. New technologies and minimally invasive surgery in gynecology. Moscow: GEOTAR-MED, 2004. 136 p.

5. Tikhomirov L. A., Lubnin D. M. uterine artery Embolization in the treatment of uterine fibroids // Questions of gynecology, obstetrics and Perinatology. 2002. No. 2. P. 83-85.

6. Sakalakala S. V. Clinico-morphological features of the endometrium in patients with simple and proliferating uterine cancer: author. ... candidate. honey. Sciences. M.: 2005, 24.

7. Kogan E. A., Skolska S. I., Morphological and functional status in patients with endometrial smimou of the uterus in the reproductive age // Ross. Bulletin of obstetrician-gynecologist, 2013, №8, 46-51.

8. Litvinova N. And. The state of the endometrium in patients with combined pathology of endo - and myometrium undergoing uterine artery embolization in the premenopausal age: author. dis. Cand. honey. Sciences. M. 2009; 24.

9. Brunereau I., Hebreteau D., S. Gallas et al. Can artery embolization in the primary treatment at can leiomyomas: technical features and prospective follow-up with clinical and sonographic examination // ASR. 2000. V. 175, No. 5. P. 1267-1272.

A method of predicting the development of endometrial hyperplasia in patients with uterine fibroids after uterine artery embolization, characterized in that prior to uterine artery embolization (UAE) for all patients, conduct diagnostic and therapeutic curettage, 6 months after embolization conduct PayPal-endometrial biopsy with subsequent pathologic examination of the biopsy, in the absence of pathology of the biopsy specimens subjected to immunohistochemical study using monoclonal antibodies to Ki-67, determine the percentage of the proliferation marker Ki-67 in the epithelium of endometrial glands - the coefficient A and in the stroma of the endometrium - factor In and calculate the prognostic index D1- if source (up to EMA) hyperplasia without atypia and D2- if source (up to EMA) endometrium, corresponding to the late phase of cell proliferation
D1=A*0.05-0.74,
where A is the percentage of the proliferation marker Ki-67 in the epithelium of the glands & �metry, and when D1more than or equal to 0, predict a relapse of endometrial hyperplasia, and in D1less than 0 make a conclusion of low risk of recurrence of endometrial hyperplasia;
D2=*0,02-0,3,
where b is a percentage of the proliferation marker Ki-67 in endometrial stroma, and D2over 0 judged a low risk of developing endometrial hyperplasia, and in D2less than or equal to 0, predict the development of endometrial hyperplasia



 

Same patents:

FIELD: medicine.

SUBSTANCE: claimed invention relates to medicine, namely to immunology, and can be applied for detection of contaminants in glucose polymers. For this purpose analysis of inflammatory response is carried out in vitro with application of cell line, which represents cell line of either macrophages or differentiable in macrophages, or cell, expressing one or several toll-like receptors (TLR) or NOD-like receptors, selected from TLR2, TLR4 and NOD2. Analysis contains the following stages: (a) placing macrophages in presence of preparation of glucose polymers, which can contain anti-inflammatory contaminants, and measuring cytokine RANTES production, with production of RANTES cytokine indicating to the fact that preparation contains contaminants capable of initiating inflammatory reaction, and (b) placing cell line, which makes it possible to detect activity of innate immunity receptor or several receptors of innate immunity, selected from TLR2 and NOD2, in presence of preparation and detection of signal of reporter gene, bound to said receptor, with detection of said activity or said signal indicates presence in preparation of contaminant, which represents receptor agonist.

EFFECT: application of claimed method makes it possible to detect contaminants of glucose polymers, and addition of components, such as MDP or LPS, in tested sample makes it possible to act synergistically with contaminants, which increases sensitivity and reduces threshold of detection, with synergetic response being registered for RANTES.

28 cl, 5 ex, 23 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: peripheral leukocyte blood values before and after a loading test are measured with the use of the gradual submaximal exercise. The method involves the differentiated recovery of different types of leukocytes from the blood to produce a preparation; a total T-cell (Tt) and active T-cell (Ta) count is determined; a Tt/Ta ratio is derived; mononuclear cells are incubated with granulocytes; a granulocyte-binding lymphocyte index (GLI) is determined in accordance with a granulocyte rosette formation (GRL - contact bound to three granulocytes) to granulocyte contact lymphocytes (GCL - contact bound to one granulocyte) ratio in the preparation; leukocyte indices: lymphocyte index (LI), immune reactivity index (IRI), adaptation index, ("CПHP") are determined; immune functional state adaptation coefficients (K) are derived for each value. Total immune functional body state TIFBS is calculated by formula TIFBS = K"спнр"+Kli+Kiri+Kgli+K"итл" before the exercise - TIFBS1 and after the exercise - TIFBS2. A specific immune functional state coefficient SIFSC is calculated by formula SIFSC = (TIFBS1+TIFBS2)/5, and a level of the immune functional SIFSC reserve is determined. If the SIFSC values are above +1.0, the level of the immune functional reserve is considered to be optimal; the SIFSC values falling within the range of 0 to 1.0 show the satisfactory reserve, whereas the SIFSC values below 0 shows the unsatisfactory reserve.

EFFECT: method enables assessing the functional body reserves with the use of combined characteristics including the adaptation body potential, immune reactivity and immune cell interaction.

1 ex

FIELD: medicine.

SUBSTANCE: DNA is recovered from peripheral venous blood. Genetic polymorphisms of tumour necrosis factor α (-308 G/A TNFα), tumour necrosis factor 1 receptor (+36 A/G TNFR1), interferon-inducible T-cell chemoattractant (A/G I-TAC), interleukin 1A (-889 C/T IL-1A), lymphotoxin α (+250 A/G Ltα) are typed by polymerase chain reaction. A high risk of developing hyperplastic processes of endometrium is predicted if detecting a combination of alleles -308 G TNFα, +36 A TNFR1, A I-TAC, -889 T IL-1A and/or a combination of alleles +36 A TNFR1, A I-TAC, -889 T IL-1A and/or a combination of alleles -308 G TNFα,+250 G Ltα, -889 T IL-1A.

EFFECT: higher accuracy.

2 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: chronic infectious-inflammatory diseases (CIIDs) are diagnosed. Clinical blood analysis and bacteriological tests are conducted. A sensibilisation index (SI) and an immune responsiveness index (IRI) are calculated; total microbial count per 1 m3 of the working space air is measured, and the total microbial number (TMN) is derived. If the TMN is less than 500 CFU/m3 with no CIIDs diagnosed accompanied by the SI of less than 1.08 standard units and the IRI of less than 13 standard units, the immunoassay is considered to be inadvisable. If the TMN falls within the range of 500-2,500 CFU/m3 with one CIID diagnosed accompanied by the SI from 1.08 to 1.3 standard units and the IRI from 13.1 to 15.7 standard units, the immunoassay with the first-level tests seems advisable. Whereas the TMN exceeding 2,500 CFU/m3 with at least two CIIDs accompanied by the SI of 1.4-1.5 standard units and the IRI of 15.8-18.3 standard units, the immunoassay with the second-level tests is thought expedient.

EFFECT: invention enables detecting the workers in need of further examination for the purpose of timely immune correction in the setting of mass routine examinations.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: DNA from peripheral venous blood is extracted. An analysis of a combination of genetic versions of polymorphous markers of genes of cytokines of the gene regulator of the activity of normal expression and secretion of T-cells (-403 G/A RANTES), macrophage protein -1β (+1931 A/T MIP 1β), factor of stromal cells (-801 G/A SDF1), interleukin -1 (-511 C/T IL-1B), monocyte chemoattractant protein -1 (C/G MCP-1), interleukin -4 (-590 C/T IL-4) is performed. An increased risk of development of a combination of uterine myoma with endometriosis and hyperplastic processes of the endometrium is predicted if the combination of alleles 403 A RANTES, G MCP-1,+1931 A MIP 1β, -590 C IL-4 or the combination of alleles -403 A RANTES,+1931 A MIP 1β, -801 G SDF1, -511 C IL-1B is identified.

EFFECT: application of the claimed method makes it possible to detect a group of patients with a risk of developing a combination of proliferative reproductive system diseases, which makes it possible to prescribe an adequate therapy to prevent further progressing of the diseases.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention deals with method of predicting level of arterial pressure in women of Russian nationality, born in Central Black Earth region of Russia. Method includes separation of DNA from lymphocytes of peripheral venous blood and analysis of genetic polymorphisms. +46G/A ADRB2 and 4a/4b eNOS by method of polymerase chain reaction Level of systolic arterial pressure in women in late pregnancy is predicted by results of multiple regression equation of the following type: Y1=15,455+2,544x1+9,946x2+0,736x3+4,716x4+0,185x5, where x1 is genetic variant in locus - 4a/4b eNOS, namely 4b4b=1; 4a4b=2; 4a4a=3; x2 is presence of preeclampsia in relatives: yes=0, no=1; x3 is level of systolic arterial pressure before pregnancy, mm Hg; x4 is presence of cardiovascular system pathology: yes=0, no=1; x5 is woman's weight before pregnancy, kg Level of diastolic arterial pressure in women in late pregnancy is predicted, for which purpose multiple regression equation of the following type is used: Y2=14,200+7,768x1-2,877x2+7,500x3+0,414x4+3,668x5, where x1 is genetic variant in locus - 4a4b eNOS, namely 4b4b+4a4b=1, 4a4a=0; x2 is genetic variant in locus +46G/A ADRB2, namely GG+GA=1, AA=0; x3 is presence of preeclapsia in relatives:yes=0, no=1; x4 is systolic arterial pressure before pregnancy, mm Hg; x5 is presence of cardiovascular system pathology: yes=0, no=1.

EFFECT: invention makes it possible to realise early prediction of increase of arterial pressure level in women in late pregnancy, will make it possible to form of women at the stage of pregravidal preparation and at early terms of pregnancy groups of high risk of developing hypertension in late pregnancy, as well as realise required therapeutic-preventive measures aimed at prevention of development of said pregnancy complication in due time.

2 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method is based on contacting a membrane test strip with an analysed fluid sample and initiating thereby a motion along the test strip membranes of reagents being parts of the sample or coating the membrane, and forming the immune complexes to be detected in the course of reactions in the membrane pores or on the surface thereof. A distinguishing feature of the presented method for antigen detection is that the test strip is coated additionally within the test sample contact area with a certain amount of specific antibodies, which react to the detected antigen expected to be found in the sample, when a fluid front moves and block a certain number of binding sites. The number of the coating free antibodies is specified so that the low content thereof in the analysed sample being of no diagnostic importance ensures blocking the binding sites completely that prevents the antigen from binding in the analysed area of the test strip and from developing a destructive staining in the analysed area.

EFFECT: presented approach enables reliable diagnosing based on the detection results of the antigens of gastrointestinal disorders, avoiding the achievement of positive test results for the low-antigen samples, which testifies to no development of the disease in an individual.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular hepatology and infectious diseases, and can be used for determination of stage of fibrous process in monitoring of patients with chronic hepatitis C. To realise method levels of blood serum cytokins are determined in patients with chronic hepatitis C with diagnosed by means of biopsy or other non-invasive method stage of fibrous process 2 times a year, with further calculation of cytokine profile integral index (CPII) on their basis, at initial stage F0 growth of CPII higher than -8 testifies to debut of fibrous changes in liver (transition to stage F1), at initial stage F1, drop of CPII below -10 testifies to transition to stage F2, at initial stage F2 growth of CPII higher than -3 testifies to transition of fibrosis to stage F3, at initial stage F3 drop of CPII below -3 testifies to development of cirrhosis.

EFFECT: determination of stage of fibrous process in monitoring of patients with chronic hepatitis C.

3 ex, 1 tbl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of predicting spontaneous onset of pregnancy in women with I and II stage of external genital endometriosis. The essence of the invention consists in the fact that before treatment in peripheral blood of women with infertility, associated with I and II stage of external genital endometriosis determined is a relative quantity of IL- IL-1β + monocytes, and if the value of the said index is 50.0% and higher in the monocytic gate the spontaneous onset of pregnancy within a year after carrying out the surgical treatment of endometriosis is predicted.

EFFECT: application of the claimed method makes it possible to predict with high accuracy the spontaneous onset of pregnancy in the women with infertility in case of I and II stage of external genital endometriosis within a year after therapeutic laparoscopy, which makes it possible to select optimal tactics of the patients' management and estimate the necessity of administering them methods of assisted reproductive technologies.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: peripheral blood serum interleukin-6 is measured by an immunoassay; if the measured level is more than 5 pg/ml, a biocontrol session of the heart rate variability is predicted to be effective and is expected to represent the total spectrum power gain of the heart rate variability combined with a drop in a regulatory system strain index in relation to references.

EFFECT: method enables the more accurate prediction of the length of the biocontrol course in order to intensify the vagal effect on the heart rate.

1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: in lacrimal liquid one should detect the content of interleukin 8 (IL-8) and that of interleukin 1 beta (IL-1β) to calculate prognostic coefficient (PC) due to dividing the first value by the second one by the following formula: At PC value being below 10.0 one should predict favorable disease flow, and at PC value being above 10.0 - unfavorable flow.

EFFECT: higher accuracy of prediction.

2 ex

FIELD: medicine, medicinal microbiology.

SUBSTANCE: method involves growing microorganism culture to be studied in solid nutrient medium followed by preparing microbial suspension and its incubation in the presence of lactoferrin. Control sample is prepared in parallel series. Control and experimental samples are incubated, supernatant is removed from bacterial cells and lactoferrin concentration is determined in supernatant of experimental and control sample by immunoenzyme analysis. Then anti-lactoferrin activity is calculated by difference of concentrations of residual lactoferrin in experimental and control samples. This method provides enhancing the sensitivity and precision in carrying out the quantitative evaluation of anti-lactoferrin activity in broad spectrum of microorganisms that is urgent in diagnosis and prognosis of diseases with bacterial etiology. Invention can be used in determination of persistent indices of microorganisms for assay of their etiological significance in pathological processes.

EFFECT: improved assay method.

3 tbl, 3 ex

FIELD: medicine, biology.

SUBSTANCE: invention relates to nutrient medium used for accumulation of cells for the following cytological and/or immunocytochemical analysis carrying out. Invention relates to medium containing salts NaCl, KCl, anhydrous CaCl2, MgSO4 x 6 H2O, MgCl2 x 6 H2O, Na2HPO4 x 2 H2O, KHPO4, NaHCO3, and also glucose and Henx's solution, 10% albumin solution and polyglucin taken in the ratio 1:1:1. Invention provides enhancing the preservation of cells.

EFFECT: improved an valuable properties of nutrient medium.

3 ex

FIELD: medicine, cardiology.

SUBSTANCE: in peripheral blood one should detect the level of CD95(+) and CD16(+) neutrophilic granulocytes and at combination of increased level of CD95(+) neutrophilic granulocytes by 4 times and more and CD16(+) neutrophilic granulocytes by 0.6 times against the norm with ECG signs of myocardial infarction one should predict lethal result of large-focal myocardial infarction.

EFFECT: higher accuracy of prediction.

FIELD: medicine, parasitology.

SUBSTANCE: one should carry out immunoenzymatic assay to detect diagnostic optic density and that of labeled immune complex in a plot's hole with tested serum measured in conventional units at wave length being 492 nm. One should calculate coefficient of antibodies concentration measured in conventional units by the following formula: CAC = (Odtsh - Odd) x 100, where CAC - coefficient of antibodies concentration, Odtsh - optic density of the hole with tested serum, Odd - diagnostic value of optic density, 100 - coefficient of serumal dilution. By CAC value one should detect the titer of antibodies to Lamblia intestinalis antigens to interpret results of the trial. The method enables to study the dynamics of disease flow.

EFFECT: higher efficiency and accuracy of diagnostics.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with studying and treating diseases of inflammatory, autoimmune and degenerative genesis. One should perform sampling of heparinized blood followed by its sedimentation to obtain blood plasma with leukocytes and centrifuging to isolate the latter which are washed against erythrocytic and serumal admixtures, and, also, it deals with calculating the number of cells in samples out of leukocytic suspension after incubation (B) for 1.5 h at 37 C in holes of plastic microplotting board, out of leukocytic suspension one should additionally prepare two samples, one should be applied to calculate total number of leukocytes before incubation (A), the second sample undergoes incubation at the same mode at addition of autoserum to calculate the number of cells remained after incubation (C). One should state upon adhesive properties of leukocytes by the index of spontaneous adhesion (D), where D=(A-B)/B.100%, and effect for enhanced cellular adhesion under the impact of autoserum should be detected by the value of K=(B-C)/C.100% at K ≥ 30%, where B - C - the number of cells undergone additional adhesion after addition of autoserum. The present innovation widens functional possibilities of the suggested method due to obtaining additional values depicting adhesive properties of blood leukocytes.

EFFECT: higher accuracy of detection.

FIELD: medicine, immunology.

SUBSTANCE: one should carry out reaction of blast-transformation, detect proliferation of T-lymphocytes activated with antibodies to CD3 in the presence of interleukin-7 (ACT IL-7) and in the presence of interleukin-7 and dexametazone (ACT IL-7 D), calculate the index for dexametazone action as the ratio of ACT IL-7 to ACT IL-7 D, moreover, the value of dexametazone action index being above 1.2 indicates increased production of cytokins that suppress T-lymphocytes in neonatals. The method enables to detect functional defect of immune system that characterizes neonatal period.

EFFECT: higher efficiency of detection.

2 ex

FIELD: medicine.

SUBSTANCE: method involves measuring forced exhalation volume per 1 s (FEV1) in l, full right ventricle evacuation time (RVE) in ms and angiotensin II value (AII) in ng/l. Discriminant relationship is built as D=0.504·RVE+3.038·FEV1 - 2.0·AII. D being less than 83.88, pulmonary hypertension occurrence is predicted within 1 year. D being equal to or greater than 83.88, no pulmonary hypertension is predicted to occur.

EFFECT: enhanced accuracy of prediction.

FIELD: medicine, medicinal immunology.

SUBSTANCE: method involves determination of heterophilic antibodies in human serum blood by the Paul-Bunnel's method relatively the level of circulating immune complexes, complement-activating properties of heterophilic antibodies by incubation of standardized ram erythrocytes with 0.8% serum for 30 ± 5 min and the following measurement of the erythrocytes lysis degree. The measurement of the effector function coefficient of heterophilic antibodies is carried out by the complement system Keff.f.h.a.-c.s. by the formula: Keff.f.h.a.-c.s. = Y/Tg.a. wherein Y means a lysis degree, %; Tg.a. means a reverse titer of heterophilic antibodies to ram erythrocytes. The damage assay is carried out by comparison of the immune status with the relative level of circulating immune complexes in serum. Method provides detection of preclinic from of immunodeficiency and autoimmune diseases that opens the possibility for their prophylaxis at most early stages of development. Invention can be used for assay of damage in the immune status in human serum blood.

EFFECT: improved method for assay.

5 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves concurrently examining anti-inflammatory IL-4 level in blood serum and lacrimal fluid. The value being within the limits of 60-70 pg/l in blood serum and 5-15 pg/l in lacrimal fluid, disease prognosis is considered to be unfavorable. The IL-4 concentration being within the limits of 90-100 pg/l in blood serum and 20-30 pg/l in lacrimal fluid, disease prognosis is considered to be favorable.

EFFECT: high accuracy of diagnosis.

Up!